UC and Broad have been involved in two interferences at the patent office. Interference No. 106,115 was the second interference between UC and Broad over patent rights to CRISPR-Cas9 technology in ...
This is a preview. Log in through your library . Abstract CRISPR/Cas9 technology has immense power to reproduce plants with desired characters and revolutionizing the field of genome engineering by ...
Cassava (Manihot esculenta Crantz, 2n = 36) is one of the most important root crops globally, particularly in tropical regions of Africa, Asia, and Latin America. It is a major source of food, ...
Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of ...
Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug ...
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...
SEOUL, South Korea, Nov. 19, 2025 /PRNewswire/ -- ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent and Trademark Office has ...
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
DUBLIN & MONTREAL--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback